Request Demo
Last update 06 Jun 2025
Atigotatug/Nivolumab
Last update 06 Jun 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms BMS-986012/Nivolumab, BMS-986489 |
Target |
Action inhibitors |
Mechanism Fuc-GM1 inhibitors(Ganglioside fucosyl GM1 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Structure/Sequence
Sequence Code 93681H
The sequence is quoted from: *****
Sequence Code 93684L
The sequence is quoted from: *****
Sequence Code 97142L
The sequence is quoted from: *****
Sequence Code 936772904H
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Atigotatug/NivolumabNCT06799286
An Open-label, Single-arm, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT06773910
An Open-label, Randomized Study of BMS-986489 (Atigotatug + Nivolumab Fixed-dose Combination) vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06646276
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
100 Clinical Results associated with Atigotatug/Nivolumab
Login to view more data
100 Translational Medicine associated with Atigotatug/Nivolumab
Login to view more data
100 Patents (Medical) associated with Atigotatug/Nivolumab
Login to view more data
100 Deals associated with Atigotatug/Nivolumab
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Extensive stage Small Cell Lung Cancer | Phase 3 | United States | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | China | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | Japan | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | Argentina | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | Australia | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | Austria | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | Belgium | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | Brazil | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | Canada | 25 Feb 2025 | |
| Extensive stage Small Cell Lung Cancer | Phase 3 | Chile | 25 Feb 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 250 | flvtpllvfb(nlqlbrankp) = rqjqbsdrgj dbnboevtow (uvsfydvcgr, 11.3 - NE) | Positive | 30 May 2025 | |||
Durvalumab | flvtpllvfb(nlqlbrankp) = uagukgcajb dbnboevtow (uvsfydvcgr, 9.3 - 16.5) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free